Salarius Pharmaceuticals Inc (SLRX)

[axelvento]

33 million in cash!!

'Seclidemstat also has the potential for treating various other cancer types. For instance, MD Anderson recently announced an investigator initiated trial studying seclidemstat in hematological cancers. In addition, Salarius hopes to study seclidemstat in other solid tumors in combination with immunotherapy or other targeted anti-cancer agents. And, with $33 million in cash as of June 30, 2021, it not only has the expertise but the financial ability to fund its clinical trials — and build a pipeline supporting company growth — for the future'.

$SLRX is looking to change the treatment paradigm by developing a less cytotoxic cancer treatment that is given as an oral tablet. Salarius’ treatment should not have the harsh side effects associated with chemotherapy, including hair loss and long-term nerve damage.

https://www.benzinga.com/general/biotech/21/10/23412584/could-the-future-hold-a-less-toxic-cancer-treatment-in-the-form-of-a-tablet?utm_campaign=partner_feed&utm_source=TechInvestorNews&utm_medium=partner_feed&utm_content=site